Period:
Draw Mode:
| Volume | 12 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ocuphire Pharma Inc | OCUP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.48 | 04:56:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.48 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 4 | 12 | - | 1.9501 - 6.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:26:38 | 1 | $ 3.74 | USD |
Ocuphire Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 73.11M | 21.01M | - | 39.85M | 17.89M | 0.85 | 2.13 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ocuphire Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCUP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.92 | 4.50 | 3.4201 | 3.80 | 915,826 | -0.44 | -11.22% |
| 1 Month | 4.00 | 4.50 | 3.4201 | 3.87 | 401,173 | -0.52 | -13.0% |
| 3 Months | 3.85 | 4.50 | 3.4201 | 3.94 | 209,881 | -0.37 | -9.61% |
| 6 Months | 3.59 | 6.60 | 3.4201 | 4.64 | 303,047 | -0.11 | -3.06% |
| 1 Year | 2.01 | 6.60 | 1.9501 | 4.00 | 235,339 | 1.47 | 73.13% |
| 3 Years | 5.93 | 13.812 | 1.7801 | 4.54 | 468,540 | -2.45 | -41.32% |
| 5 Years | 5.93 | 13.812 | 1.7801 | 4.54 | 468,540 | -2.45 | -41.32% |
Ocuphire Pharma Description
| Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |